Loading
Nasopharyngeal Carcinoma / Immune Checkpoint Inhibitors / Nasopharyngeal Neoplasms · Journal article
Human Vaccines & Immunotherapeutics · August 17, 2026
A consensus or society position rather than new primary data.
This review synthesizes evidence that PD-1/PD-L1 inhibitors, as monotherapy or combined with chemotherapy or antiangiogenic agents, improve outcomes in recurrent/metastatic nasopharyngeal carcinoma, and that incorporation into induction, concurrent, and adjuvant phases shows potential benefit in locoregionally advanced disease. Key unresolved challenges include optimal patient selection, treatment timing and duration, immune-related adverse event management, and validation of biomarkers such as PD-L1 expression and plasma EBV-DNA levels for risk stratification.
Narrative review. Patients with nasopharyngeal carcinoma across disease stages (recurrent/metastatic and locoregionally advanced), with emphasis on epidemiology (primarily Southeast Asia and Southern China) and immunotherapy eligibility. Intervention: Programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors as monotherapy, or combined with chemotherapy or antiangiogenic agents; immunotherapy integrated into induction, concurrent chemoradiotherapy, and adjuvant treatment phas….
PD-1/PD-L1 inhibitors administered as monotherapy or combined with chemotherapy or antiangiogenic agents can significantly improve outcomes in recurrent/metastatic NPC Incorporating immunotherapy into induction, concurrent chemoradiotherapy, and adjuvant phases has demonstrated potential benefits in enhancing antitumor immune responses and reducing disease recurrence incidence in locoregionally advanced NPC Biomarkers including PD-L1 expression and plasma Epstein-Barr virus-DNA levels show promise in facilitating risk stratification and tailoring individualized treatment regimens
Challenges and gaps (patient selection, timing, duration, adverse event management) are identified but not quantified with comparative outcome data
Clinicians should recognize immunotherapy as a cornerstone of management for both R/M NPC and LANPC, with PD-1/PD-L1 inhibitors showing benefit across monotherapy and combination strategies. However, the review underscores that optimal patient selection, treatment sequencing, and biomarker-guided stratification remain open questions requiring further prospective evidence.
This is a comprehensive narrative review synthesizing evidence on immunotherapy's current role in nasopharyngeal carcinoma management, drawing on completed and ongoing clinical trials to inform clinical practice and research priorities.
As stated by the source record.
Clinicians should recognize immunotherapy as a cornerstone of management for both R/M NPC and LANPC, with PD-1/PD-L1 inhibitors showing benefit across monotherapy and combination strategies. However, the review underscores that optimal patient selection, treatment sequencing, and biomarker-guided stratification remain open questions requiring further prospective evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Immunotherapy has emerged as a cornerstone in the management of both recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) and locoregionally advanced NPC (LANPC). Evidence indicates that programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors, whether administered as monotherapy or in combination with chemotherapy or antiangiogenic agents, can significantly improve outcomes in R/M NPC. For LANPC, incorporating immunotherapy into induction, concurrent chemoradiotherapy, and adjuvant phases has demonstrated potential benefits in enhancing antitumor immune responses and reducing the incidence of disease recurrence. However, challenges persist regarding the identification of optimal patient populations, the determination of optimal timing and duration of treatment, and the management of immune-related adverse events. Biomarkers such as PD-L1 expression and plasma Epstein-Barr virus-DNA levels show promise in facilitating risk stratification and tailoring individualized treatment regimens. Accordingly, this review provides a comprehensive review of immunotherapy for NPC, evaluating current progress an persistent challenges by drawing insights from both completed and ongoing clinical trials.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.